DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia

British Journal of Haematology

Volumn 159, Issue 3, 2012, Pages 373-376

  Leo, Elisa ^a   Mancini, Manuela ^a   Aluigi, Michela ^a   Castagnetti, Fausto ^a   Martinelli, Giovanni ^a   Barbieri, Enza ^a   Santucci, Maria A ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Apoptosis resistance; BCL2L11; BCR ABL1 tyrosine kinase; Chronic myeloid leukaemia; DNMT1

Indexed keywords

BCR ABL PROTEIN; BCR ABL1 PROTEIN; PROTEIN BCL 2; PROTEIN BCL2L11; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

APOPTOSIS; BCL2L11 GENE; BCR ABL1 GENE; CANCER SURVIVAL; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; DNA METHYLATION; EDITORIAL; FUSION GENE; GENE DELETION; GENE EXPRESSION REGULATION; HUMAN; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DISEASE PROGRESSION; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE PROTEINS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS;

EID: 84867474277     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12023     Document Type: Editorial

References (10)

1. Aichberger, K.J., Mayerhofer, M., Krauth, M.T., Vales, A., Kondo, R., Derdak, S., Pickl, W.F., Selzer, E., Deininger, M., Druker, B.J., Sillaber, C., Esterbauer, H. & Valent, P. (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Research, 65, 9436-9444.
2. Aichberger, K.J., Jagani, Z., Song, K., Kutok, M.R., Melet, A., Santos, T., Grassian, A., Ghaffari, S., Wu, C., Ren, R., Yeckes Rodin, H., Miller, K. & Khosravi-Far, R. (2009) Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Research, 69, 6546-6555.
3. Boultwood, J. & Wainscoat, J.S. (2007) Gene silencing by DNA methylation in haematological malignancies. British Journal of Haematology, 138, 3-11.
4. Jelinek, J., Gharibyan, V., Estecio, M.R.H., Kondo, K., He, R., Chung, W., Lu, Y., Zhang, N., Liang, S., Kantarjian, H.M., Cortes, J.E. & Issa, J.P.J. (2011) Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortnened survival in chronic myelogenous leukemia. PLoS ONE, 6, e22110.
5. Kuribara, R., Honda, H., Matsui, H., Shinjyo, T., Inukai, T., Sugita, K., Nakazawa, S., Hirai, H., Ozawa, K. & Inaba, T. (2004) Roles of Bim in apoptosis of normal and Bcr-Abl-expressing hematopoietic progenitors. Molecular and Cellular Biology, 24, 6172-6183.
6. Kuroda, J., Puthalakath, H., Cragg, M.S., Kelly, P.N., Bouillet, P., Huang, D.C.S., Kimura, S., Ottmann, O.G., Druker, B.J., Villunger, A., Roberts, A.W. & Strasser, A. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings National Academy Science USA, 103, 14907-14912.
7. Mancini, M., Veljkovic, N., Leo, E., Aluigi, M., Borsi, E., Galloni, C., Iacobucci, I., Barbieri, E. & Santucci, M.A. (2012) Cytoplasmatic compartimentalization by Bcr-Abl promotes TET2 loss-of-function in chronic myeloid leukemia. Journal of Cellular Biochemistry, 113, 2765-2774.
8. Ng, K.P., Hillmer, A.M., Chuah, C.T., Juan, W.C., Ko, T.K., Teo, A.S., Ariyaratne, P.N., Takahashi, N., Sawada, K., Fei, Y., Soh, S., Lee, W.H., Huang, J.W., Allen, Jr, J.C., Woo, X.Y., Nagarajan, N., Kumar, V., Thalamuthu, A., Poh, W.T., Ang, A.L., Mya, H.T., How, G.F., Yang, L.Y., Koh, L.P., Chowbay, B., Chang, C.T., Nadarajan, V.S., Chng, W.J., Than, H., Lim, L.C., Goh, Y.T., Zhang, S., Poh, D., Tan, P., Seet, J.E., Ang, M.K., Chau, N.M., Ng, Q.S., Tan, D.S., Soda, M., Isobe, K., Nöthen, M.M., Wong, T.Y., Shahab, A., Ruan, X., Cacheux-Rataboul, V., Sung, W.K., Tan, E.H., Yatabe, Y., Mano, H., Soo, R.A., Chin, T.M., Lim, W.T., Ruan, Y. & Ong, S.T. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior response to tyrosine kinase inhibitors in cancer. Nature Medicine, 18, 521-528.
9. San José-Eneriz, E., Agirre, X., Jiménez-Velasco, A., Cordeu, L., Martin, V., Arqueros, V., Garate, L., Fresquet, V., Cervantes, F., Martinez-Climent, J.A., Heiniger, A., Torres, A., Prosper, F. & Roman-Gomez, J. (2009) Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukemia. European Journal of Cancer, 45, 1877-1889.
10. Youle, R.J. & Strasser, S. (2008) The BCL-2 protein family: opposing activities that mediate cell death. Nature Reviews. Molecular Cell Biology, 9, 47-59.